AiverseWorld logo

AiverseWorld

Compare

Compare AI tools with a clear side-by-side workflow

Start with two products, then move into pricing, capability, platform fit, and practical tradeoffs.

Selected comparison

Flatiron Health AI vs Tempus AI

This comparison was retrieved by database IDs selected from the catalog.

Flatiron Health AI favicon

Flatiron Health AI

Flatiron Health (Roche)

Tempus AI favicon

Tempus AI

Tempus

Overview
Rating
—
—
Category
Developer Tools
Developer Tools
Subcategory
AI Oncology Real-World Data Platform
AI Precision Medicine
Company
Flatiron Health (Roche)
Tempus
Status
Active
Active
Launch year
2021
2015
Tags
oncologyreal-world-evidenceaihealthcarepharmaceuticalnlp
precision-medicineoncologyaigenomicsclinical-researchhealthcare
Pricing
Starting price
FreeBest value
Free
Pricing model
Enterprise
Enterprise
Free plan
No
No
Free trial
✕
✕
Pricing notes

Enterprise licensing to pharmaceutical companies and cancer centres. No public pricing. Subsidiary of Roche.

Enterprise licensing to health systems, pharmaceutical companies, and research institutions. No public pricing.

Capabilities
Best for
Oncology drug development and regulatory submissionsReal-world evidence for pharmaceutical researchCancer centre quality improvementTreatment pattern analysisPost-market surveillance studies
Precision oncology treatment decisionsClinical trial patient matchingDrug discovery researchGenomic analysisPersonalised cancer medicine
Target audience
Pharmaceutical oncology teamsRegulatory affairs scientistsCancer centre medical directorsClinical research organisationsHealth economists
OncologistsCancer research institutionsPharmaceutical companiesHealth systemsClinical trial teams
AI type
Document Analysis LLM
ML Platform
Modalities
TextDocumentData
DataText
Technical
Model provider
Flatiron Health
Tempus
Model names
—
—
API available
✕
✕
Open source
✕
✕
Deployment
EnterpriseSaaS
Enterprise
Platforms
WebAPI
WebAPI
Integrations
EHR systemsClinical data systemsRegulatory submission toolsAPI
EHR integrationsPharmaceutical platformsResearch systemsAPI
Team collaboration
✕
✓
Trust & security
Security

HIPAA compliant with BAA. SOC 2 Type II. GDPR compliant for EU deployments. IRB approval for research datasets. FDA-accepted data quality standards.

HIPAA compliant. SOC 2 Type II. ISO 27001. Patient genomic and clinical data handled under HIPAA protections with appropriate de-identification for research use.

Privacy notes

Patient health data processed under strict HIPAA BAA and applicable research ethics frameworks. De-identification and IRB protocols govern research dataset access.

Patient genomic and clinical data processed under HIPAA protections. Research use data is de-identified per HIPAA standards. Enterprise includes comprehensive data handling agreements.

Verdict
Pros
  • 9 million+ patient oncology database is one of the most comprehensive real-world oncology datasets available for pharmaceutical research
  • FDA-accepted real-world evidence from multiple regulatory submissions provides unmatched regulatory validation
  • NLP curation of clinical notes extracts structured data inaccessible through structured EHR data alone
  • Roche ownership provides stability and pharmaceutical partnership pipeline
  • One of the largest clinical and molecular data libraries in oncology
  • AI treatment insights grounded in real-world evidence from similar patients
  • Clinical trial matching significantly reduces pharmaceutical patient recruitment costs
  • Public company (NASDAQ: TEM) with strong financial validation
Cons
  • Roche ownership creates potential conflict of interest concerns for pharmaceutical competitors as data partners
  • Real-world evidence database access requires partnership agreements limiting accessibility
  • Clinical note NLP accuracy requires ongoing validation — structured EHR data remains more reliable for some variables
  • Enterprise-only with high pricing inaccessible to small practices
  • Primarily focused on oncology — less applicable in other disease areas
  • AI insights are supportive tools, not clinical decision replacements requiring physician judgment

Trending comparisons

120 curated matchups

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement